A California woman living with hepatitis C virus (HCV) is suing Anthem Blue Cross, her health insurer, for refusing to cover the cost of her HCV treatment, the Los Angeles Times reports.

Shima Andre, a resident of West Hollywood, alleges in the lawsuit that Anthem recently sent her a denial letter for Gilead’s $99,000 combination HCV drug Harvoni (sofosbuvir/ledipasvir), saying the treatment was “not medically necessary.” The insurer’s reasoning was that Andre, 42, does not yet have advanced liver damage.

Harvoni, which was approved in 2014, is a once-a-day pill taken for eight to 12 weeks that can cure hep C with more than 90 percent efficacy. U.S. recommendations surrounding the drug have only put patients with severe liver scarring on the “high priority” list for treatment, which many insurers have used to substantially limit the number of patients they choose to treat.

The lawsuit, filed in the Los Angeles County Superior Court, accuses Anthem of breach of contract, infliction of emotional distress and unfair business practices. It is also seeking certification as a class-action case, which would allow other people who were denied the drug to join the suit.

“I can’t believe that they demand that a person get sicker before they’ll pay for a cure,” said Andre. “If there’s a cure for something and you have health insurance, they should cover it.”